HIV 相关淋巴瘤。
HIV-related lymphomas.
机构信息
Medical Oncology and Immune-related Tumours, Centro di Riferimento Oncologico (CRO) di Aviano IRCCS, National Cancer Institute, Aviano.
Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.
出版信息
Curr Opin Oncol. 2022 Sep 1;34(5):439-445. doi: 10.1097/CCO.0000000000000890. Epub 2022 Jul 27.
PURPOSE OF REVIEW
To summarize the recent evidence on the pathology, current standard of care and recent advances in the treatment of HIV-related lymphomas.
RECENT FINDINGS
Lymphomas remain a major cause of morbidity and mortality in people living with HIV, even in the era of combination antiretroviral therapy (cART). However, treatment outcomes for these malignancies have improved in recent decades, due to full-dose chemotherapy, effective cART and supportive care. Recent advances include the identification of novel driving signaling pathways as promising molecular targets to improve lymphoma outcomes.
SUMMARY
Patients with HIV-related lymphomas who receive effective cART should be treated like the general population.
目的综述
总结 HIV 相关淋巴瘤的病理学、当前标准治疗和治疗新进展的最新证据。
最新发现
即使在联合抗逆转录病毒治疗（cART）时代，淋巴瘤仍然是 HIV 感染者发病和死亡的主要原因。然而，由于全剂量化疗、有效的 cART 和支持性护理，这些恶性肿瘤的治疗结果在最近几十年有所改善。最近的进展包括鉴定新的驱动信号通路，这些通路作为改善淋巴瘤结果的有前途的分子靶点。
总结
接受有效 cART 的 HIV 相关淋巴瘤患者应与普通人群一样进行治疗。
Zotero 插件